Immunometabolic predictive factors in Merkel cell carcinoma (MCC) patients treated with avelumab.

被引：0
|
作者：
Badalamenti, Giuseppe
Incorvaia, Lorena
Algeri, Laura
Carreca, Ignazio Ugo
Brando, Chiara
Madonia, Giorgio
Peri, Marta
Cucinella, Alessandra
Perez, Alessandro
Barraco, Nadia
Russo, Tancredi Didier Bazan
Pomi, Federica Li
Carreca, Anna Paola
Gristina, Valerio
Galvano, Antonio
Iovanna, Juan
Fanale, Daniele
Bazan, Viviana
Russo, Antonio
Carreca, Ignazio Ugo
机构：
[1] Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, Palermo, Italy
[2] Univ Sch Med, Palermo, Italy
[3] Univ Palermo, Dept Surg Oncol & Oral Sci, Palermo, Italy
[4] Univ Sch Med, Messina, Italy
[5] Inserm, U624 Stress Cellulaire, Marseille, France
[6] Univ Palermo, Palermo, Italy
[7] E Majorana Fdn Ctr Sci Culture, Int Sch Med Sci, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21525
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (US) from SPEAR-Merkel: Study informing treatment pathway decisions in Merkel cell carcinoma (MCC).
    Bhanegaonkar, Abhijeet
    Liu, Frank Xiaoqing
    Kim, Ruth
    Boyd, Marley
    Fulcher, Nicole
    Krulewicz, Stan
    Kasturi, Vijay
    Cowey, Charles Lance
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [32] Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (US) from SPEAR-Merkel -Study informing treatment Pathway dEcisions in Merkel cell cARcinoma (MCC).
    Cowey, Charles Lance
    Liu, Frank Xiaoqing
    Kim, Ruth
    Boyd, Marley
    Fulcher, Nicole
    Krulewicz, Stan
    Kasturi, Vijay
    Bhanegaonkar, Abhijeet
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
    Bullement, Ash
    Nathan, Paul
    Willis, Anna
    Amin, Amerah
    Lilley, Cameron
    Stapelkamp, Ceilidh
    Hatswell, Anthony
    Pescott, Chris
    Bharmal, Murtuza
    PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 377 - 390
  • [34] Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
    Ash Bullement
    Paul Nathan
    Anna Willis
    Amerah Amin
    Cameron Lilley
    Ceilidh Stapelkamp
    Anthony Hatswell
    Chris Pescott
    Murtuza Bharmal
    PharmacoEconomics - Open, 2019, 3 : 377 - 390
  • [35] Hyperprogression of Merkel cell carcinoma after avelumab treatment
    Pirker, R.
    Fink, A.
    Stella, A.
    Stifter, L.
    Posch, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (05) : E675 - E677
  • [36] Avelumab and other recent advances in Merkel cell carcinoma
    Bommareddy, Praveen K.
    Kaufman, Howard L.
    FUTURE ONCOLOGY, 2017, 13 (30) : 2771 - 2783
  • [37] Avelumab effective against Merkel-cell carcinoma
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2016, 13 (11) : 652 - 652
  • [38] Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
    Bharmal, Murtuza
    Kearney, Mairead
    Zheng, Ying
    Phatak, Hemant
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 349 - 359
  • [39] Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment
    Zijlker, L.
    Levy, S.
    Wolters, W.
    van Thienen, H. V.
    van Akkooi, A. C. J.
    Tesselaar, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S687 - S688
  • [40] Avelumab in Patients with metastatic Merkel Cell Carcinoma - A Question of the Length of the Therapy Interval?
    Boettjer, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 88 - 88
12345